Egan, Michael, Yaari, Roy, Liu, Lian, Ryan, Michael, Peng, Yahong, Lines, Christopher, Michelson, David

We performed a clinical trial to evaluate the effects of the histamine subtype-3 receptor inverse agonist MK- 0249 on cognition in AD patients. Mild-to-moderate AD patients were randomized 1:1 to 4 weeks of double-blind daily treatment with oral MK-0249 5-mg or placebo. Pharmacokinetic and PET data suggested that MK-0249 5-mg daily would achieve approximately 85% […]

Pasqualetti, Patrizio, Bonomini, Cristina, Dal Forno, Gloria, Paulon, Luca, Sinforiani, Elena, Marra, Camillo, Zanetti, Orazio, Rossini, Paolo Maria

Background and Aims: Epidemiological studies have examined the association between the use of non-steroidal anti-inflammatory drugs (NSAIDs) and the risk of Alzheimer’s disease (AD). Recently, a variety of experimental studies indicates that a subset of NSAIDs, such as ibuprofen or flurbiprofen, also have Abeta-lowering properties in both AD transgenic mice and cell cultures of peripheral, […]

Green, Robert C., Schneider, Lon S., Amato, David A., Beelen, Andrew P., Wilcock, Gordon, Swabb, Edward A., Zavitz, Kenton H.

Context: Amyloid-beta peptide (Abeta(42)) has been implicated in the pathogenesis of Alzheimer disease (AD). Tarenflurbil, a selective Abeta(42)-lowering agent, demonstrated encouraging results on cognitive and functional outcomes among mildly affected patients in an earlier phase 2 trial.; Objective: To determine the efficacy, safety, and tolerability of tarenflurbil.; Design, Setting, and Patients: A multicenter, randomized, double-blind, […]